Lupin inches up on getting USFDA’s nod for Emtricitabine, Tenofovir Disoproxil Fumarate Tablets

Lupin is currently trading at Rs. 1238.50, up by 4.95 points or 0.40% from its previous closing of Rs. 1233.55 on the BSE.

The scrip opened at Rs. 1242.00 and has touched a high and low of Rs. 1242.00 and Rs. 1234.50 respectively. So far 2579 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 828.65 on 27-Jul-2020.

Last one week high and low of the scrip stood at Rs. 1267.50 and Rs. 1212.60 respectively. The current market cap of the company is Rs. 55974.91 crore.

The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 40.46% and 12.69% respectively.

Lupin has received approval for its Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Truvada Tablets, 200 mg/300 mg, of Gilead Sciences, Inc. The product will be manufactured at Lupin’s facility in Nagpur, India.Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (RLD: Truvada) had estimated annual sales of $2.1 billion in the U.S.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Download App to read Latest News Today

Leave a Comment